Genovefa Papanicolaou, MD, PhD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    AiCuris
    Topic:
    CMV, Herpes simplex, Adenovirus
    Date added:
    10/10/2026
    Date updated:
    10/10/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Merck &Co
    Topic:
    CMV, Herpes simplex, Adenovirus
    Date added:
    10/10/2026
    Date updated:
    10/10/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Genentech
    Topic:
    CMV, Herpes simplex, Adenovirus
    Date added:
    10/10/2026
    Date updated:
    10/10/2026
    Relationship end date:
    03/01/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Symbio
    Topic:
    CMV, Herpes simplex, Adenovirus
    Date added:
    10/10/2026
    Date updated:
    10/10/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Takeda
    Topic:
    CMV, Herpes simplex, Adenovirus
    Date added:
    10/10/2026
    Date updated:
    10/10/2026
  • Attribution:
    Self
    Type of financial relationship:
    Researcher
    Ineligible company:
    Merck&Co, Aicuris
    Date added:
    10/10/2026
    Date updated:
    10/10/2026
  • Attribution:
    Self
    Type of financial relationship:
    Speaker
    Ineligible company:
    Taekeda, Merck &Co
    Date added:
    10/10/2026
    Date updated:
    10/10/2026
Return to Navigating Modern CMV Antivirals: Applying Guideline Updates to Clinical Practice